Azithromycin treatment of gingival hyperplasia in kidney transplant recipients is effective and safe

Citterio, Franco; Pinto, Andréia; Borzi, Mauro; Scatà, Maria Carmela; Foco, Maurizio; Pozzetto, U; Castagneto, Marco

doi:10.1016/s0041-1345(01)01973-x

Cited by 27 publications

(23 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All of the reports involved renal transplant recipients (total n = 124) who developed cyclosporine‐induced gingival hyperplasia and were treated with a short‐course (3–5 days) azithromycin. As calcium channel blockers and anticonvulsant agents have also been associated with gingival hyperplasia, one trial excluded patients receiving phenytoin (9), one trial excluded patients receiving phenytoin or nifedipine (10), one trial excluded patients in whom phenytoin or any calcium channel blocker was initiated during the study period (14), and in the remainder it was unknown or not stated whether patients could have received these agents concomitantly (6–8, 11–13). Follow‐up periods ranged from 7 days to 24 months, and the majority of studies included baseline data (cyclosporine and serum creatinine levels, cyclosporine dose) for comparative purposes.…”

Section: Resultsmentioning

confidence: 99%

“…Follow‐up periods ranged from 7 days to 24 months, and the majority of studies included baseline data (cyclosporine and serum creatinine levels, cyclosporine dose) for comparative purposes. Improvement in gingival hyperplasia was measured using simplistic grading systems (6, 7, 10, 12, 14), gingival biopsy (10), surrogate dental measures (9), patient self‐reporting of symptom change (6–13), qualitative assessment by clinician (8, 12, 13), and photographic documentation (7, 9, 12, 13).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Is oral azithromycin effective for the treatment of cyclosporine-induced gingival hyperplasia in cardiac transplant recipients?

Strachan

Burton²,

Pearson

2003

Journal of Clinical Pharmacy and Therapeutics

View full text Add to dashboard Cite

Anecdotal evidence suggests that azithromycin is effective for the treatment of cyclosporine-induced gingival hyperplasia in solid-organ transplant recipients. We present the cases of two heart transplant patients who insidiously developed gingival hyperplasia, likely because of immunosuppression with cyclosporine, which was treated with azithromycin. Evidence supporting the efficacy of azithromycin in the treatment of cyclosporine-induced gingival hyperplasia in solid organ transplant recipients was searched for, identified, and then critically assessed. While no data were found specifically evaluating azithromycin in cardiac transplant patients, there were nine pertinent papers identified that evaluated the clinical question of interest in the renal transplant population [Wahlstrom et al. (1995) The New England Journal of Medicine 332, 753; Boran et al. (1996) Transplantation Proceedings 28, 2316; Gomez et al. (1997) Nephrology Dialysis Transplantation 12, 2694; Ljutic (1997) Dialysis & Transplantation 26, 787; Puig et al. (1997) Transplantation Proceedings 29, 2379; Nash et al. (1998) Transplantation 65, 1611; Nowicki et al. (1998) Annals of Transplantation 3, 25; Wirnsberger et al. (1998) Transplantation Proceedings 30, 2117; Citterio et al. (2001) Transplantation Proceedings 33, 2134]. These studies and case reports are summarized. While more evidence is required to support routine use of azithromycin for the treatment of cyclosporine-induced gingival hyperplasia in cardiac transplant recipients, preliminary published evidence from renal transplant patients is certainly favourable.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Is oral azithromycin effective for the treatment of cyclosporine-induced gingival hyperplasia in cardiac transplant recipients?

Strachan

Burton²,

Pearson

2003

Journal of Clinical Pharmacy and Therapeutics

View full text Add to dashboard Cite

show abstract

“…Because the mechanical treatment used in the present method and FMD was the same, it could be assumed that the differences were due to the oral administration of antibiotics and the action of azithromycin. There are some reports 28–30 that azithromycin affects remodeling of the periodontium.…”

Section: Discussionmentioning

confidence: 99%

One‐Stage Full‐Mouth Versus Partial‐Mouth Scaling and Root Planing During the Effective Half‐Life of Systemically Administered Azithromycin

Yashima

Gomi

Maeda

et al. 2009

Journal of Periodontology

110

View full text Add to dashboard Cite

show abstract

“…[1316171819] Although Azi has also been observed to be effective in improving DIGO but this conclusion still needs to be explored. [9101120] and therefore, the present study was undertaken to evaluate the efficacy of Azi in inhibiting the GO caused by CsA + Nf combination therapy in SD rat model.…”

Section: Discussionmentioning

confidence: 99%

Effect of azithromycin on gingival overgrowth induced by cyclosporine A + nifedipine combination therapy: A morphometric analysis in rats

Ratre¹,

Mehta

2016

J Indian Soc Periodontol

View full text Add to dashboard Cite

Background:Drug-induced gingival overgrowth (DIGO) is a well-known adverse effect of cyclosporine A (CsA) and nifedipine (Nf) therapy. The aim of the present morphometric study was to evaluate the effect of azithromycin (Azi) on the combined GO in rats induced by CsA + Nf combination.Materials and Methods:Thirty Sprague-Dawley male rats were randomly divided equally into three groups. Group 1 (control) received olive oil only; Group 2 received a combination of CsA and Nf in olive oil throughout the study period; Group 3 received CsA + Nf combination therapy, and Azi was added for 1 week in the 5th week. All the drugs were delivered by oral route. Impressions of the mandibular central incisal regions were taken, and study models were prepared at baseline and biweekly up to the 8 weeks. Statistical analysis was done by one-way analysis of variance and intergroup comparisons were made using Tukey's post hoc analysis.Results:Significant GO was evident in Group 2 and Group 3 rats when compared to Group 1. However, in Group 3 (Azi), GO was observed up to the 4th week, but a significant decrease in GO was noticed during 6–8th week after the administration of Azi in 5th week.Conclusion:Azi is an effective drug in the remission of DIGO induced by combined therapy of CsA + Nf and thereby can be considered as a useful therapeutic regimen in minimizing the DIGO in transplant patients.

show abstract

Azithromycin treatment of gingival hyperplasia in kidney transplant recipients is effective and safe

Cited by 27 publications

References 10 publications

Is oral azithromycin effective for the treatment of cyclosporine-induced gingival hyperplasia in cardiac transplant recipients?

Is oral azithromycin effective for the treatment of cyclosporine-induced gingival hyperplasia in cardiac transplant recipients?

One‐Stage Full‐Mouth Versus Partial‐Mouth Scaling and Root Planing During the Effective Half‐Life of Systemically Administered Azithromycin

Effect of azithromycin on gingival overgrowth induced by cyclosporine A + nifedipine combination therapy: A morphometric analysis in rats

Contact Info

Product

Resources

About